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Several  non-invasive  imaging  techniques  are  used  to investigate  the  effect  of  pathologies  and  treatments
over  time  in mouse  models.  Each  preclinical  in  vivo  technique  provides  longitudinal  and  quantitative
measurements  of  changes  in  tissues  and  organs,  which  are  fundamental  for the  evaluation  of  alterations
in phenotype  due  to pathologies,  interventions  and  treatments.  However,  it  is  still  unclear  how  these
imaging  modalities  can  be  used  to study  ageing  with  mice  models.  Almost  all  age  related  pathologies  in
mice such  as osteoporosis,  arthritis,  diabetes,  cancer,  thrombi,  dementia,  to name  a few,  can  be imaged
in  vivo  by  at  least  one  longitudinal  imaging  modality.  These  measurements  are the  basis  for  quantiﬁcation
of  treatment  effects  in the  development  phase  of  a novel  treatment  prior  to  its  clinical  testing.  Further-
more,  the  non-invasive  nature  of such  investigations  allows  the assessment  of  different  tissue  and  organ
phenotypes  in  the  same  animal  and over  time,  providing  the  opportunity  to  study  the  dysfunction  ofongitudinal multiple  tissues  associated  with  the ageing  process.
This  review  paper  aims to  provide  an  overview  of the applications  of the most  commonly  used
in vivo  imaging  modalities  used  in mouse  studies:  micro-computed-tomography,  preclinical  magnetic-
resonance-imaging,  preclinical  positron-emission-tomography,  preclinical  single  photon  emission
computed  tomography,  ultrasound,  intravital  microscopy,  and  whole  body  optical  imaging.
© 2016  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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. Purpose of the review
.1. Ageing mice and their application in preclinical research
Animal models, in particular mouse models, of human disease
ave become a fundamental component of preclinical research.
ice have a similar anatomy and physiology to humans when
ompared to other non-mammalian models such as drosophila
nd zebraﬁsh (Rosenthal and Brown, 2007). However, most impor-
antly, many biological processes and pathways are conserved
etween mice and humans including those most related to
etabolism and stress response, two of the overriding aspects of
isease progression. Additionally, mice and humans share over 95%
f their genes, which paired with decades of genetic studies make
ice a formidable tool for the investigation of mammalian gene
unction in health and disease (Justice et al., 2011; Rosenthal and
rown, 2007). Murine models can allow researchers to investigate
he effect of pathologies and treatments in a more detailed manner
han it is possible in clinical studies. Changes in tissues and can be
racked organs over time, with high accuracy and non-invasively.
or a large body of human diseases, the primary or major risk factor
mplicated in disease development is ageing (Niccoli and Partridge,
012). Age related diseases pose a huge socio-economic burden
or both developed and developing nations. For example, in the
K in 2013, the overall economic impact of dementia was 26.3
illion pounds and with analysts forecasting continued increases .  .  .  .  . . . .  . .  .  . . . . . .  .  . . . . . .  . . . . .  . . .  . . . .  . . .  . . . . .  . . . .  .  . . . .  . .  . . .  .  .  .  . . .  .  .  . . . . . .  . . .  110
in ageing populations, the burden posed by these diseases is only
expected to rise (Prince et al., 2014; Suman and Beard, 2011). There-
fore, it is sensible for researchers to move towards the use of aged
mice in order to better understand age related diseases. The term
“age related disease” covers an extremely broad ﬁeld of study and
to complement this, a broad range of novel aged mouse models
will be required. Aged mice themselves are a relatively novel con-
cept and their use will yield a whole host of new challenges with
regards to their development, care and phenotyping. Addition-
ally, the high costs associated with the time required to develop
genetically modiﬁed models makes the choice of the appropriate
model fundamentally important (Benjamin et al., 2006). Extensive
systems are already in place for the study of a huge number of phe-
notypes in mice (Ayadi et al., 2012; Ferruzzi et al., 2013; Hoit, 2004;
Lee et al., 2014; Raman et al., 2007; Rozman et al., 2014; Schoﬁeld
et al., 2012), but to move forwards and tackle new challenges, scien-
tists rely on the continual development of novel technique that can
help them study and understand mice in increasingly robust and
efﬁcient ways. One group of techniques that is playing an increas-
ingly important role in facilitating the use of aged mice models
is that based around in vivo imaging. Indeed, there is a growing
interest in applying in vivo imaging modalities to study ageing in
laboratory mice, in order to acquire a more comprehensive under-
standing of the mechanisms involved in the ageing process and
identify dysfunction of multiple tissues (Lin et al., 2014), to identify
biomarkers of early onset of age related diseases (Lai et al., 2004)
ing an
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nd to test novel interventions (Stodieck et al., 2014; Zhang et al.,
015). These techniques can be used for providing both anatomical
nd functional information from the cellular level up to the whole
rganism. Thanks to the improvement over the past years, some of
hese modalities (e.g. functional or molecular imaging) have largely
ncreased their time and space resolution, being close now to phys-
cal limits of dose or ﬁeld strengths. In vivo imaging can be applied
o study different aspects of ageing and the approaches presented
n this review can be combined in order to quantitatively charac-
erize the tissues and organ phenotypes longitudinally, leading to
 comprehensive investigation of age-related dysfunction of mul-
iple tissues. In addition, these methods applied to mice models
ave the potential of evaluating healthy ageing and frailty, which
re difﬁcult to assess in humans, providing a framework to test the
ffect of novel interventions on several end points.
. In vivo imaging techniques
.1. Methods
This review focuses on the most commonly used in vivo imaging
echniques that can be applied pre-clinically to mouse models and
an be used for the study of ageing: micro computed tomography
micro-CT), preclinical magnetic resonance imaging (preclinical-
RI), preclinical positron emission tomography (preclinical-PET),
reclinical Single Photon Emission Computed Tomography (SPECT),
ltrasound (US), intravital microscopy and whole body optical ﬂu-
rescence imaging. As the topic is very broad and speciﬁc reviews
an be found with details about each technique, the goal of this
anuscript is to provide an overview of the available imaging
odalities, without going into the details of the physics behind each
echnique. In addition, we will highlight the potential for combin-
ng modalities and investigating the same animal longitudinally in
rder, for example, to study dysfunction of multiple tissues associ-
ted with ageing. In the following seven sections, the review aims
o underline the breadth of applications for the most used in vivo
maging techniques, their main applications, potential and limita-
ions.
In Section 3 and Table 1 we report the advantages and limi-
ations of the application of such techniques to study ageing or
ge-related pathologies in mouse models.
.2. Preclinical micro computed tomography (micro-CT)
.2.1. Technique
Micro-computed tomography (micro-CT) is an X-ray imaging
odality that allows the non-destructive analysis of the 3D archi-
ectural properties of an object. The sample or animal to be scanned
s placed between a microfocus X-ray tube, which emits X-rays
ollimated and ﬁltered to narrow the energy spectrum, and a 2D
harge-coupled device (CCD) array, which records the attenuated
-Rays after passing through the scanned object. The object is
otated during the scan and the projections taken in each scan-
ing position are reconstructed into a 3D image. In the last two
ecades, and with an achievable isotropic voxel size down to about
ne micron, micro-CT has become the gold standard approach
or evaluating 3D micro-architectural properties of small animal
ones (Bouxsein et al., 2010). This imaging modality is routinely
sed ex-vivo, in endpoint animal studies of bone diseases, to pri-
arily assess the effect of interventions on bone health (Pierroz
t al., 2010; Sugiyama et al., 2008). More recently, the use of
n-vivo micro-CT has proven extremely valuable in monitoring,
on-invasively, spatio-temporal changes in bone micro-structure
ith age and/or disease (Fig. 1-A,B). It has the advantage that, by
easuring the properties of the same bone, of the same animal, overd Development 160 (2016) 93–116 95
time, the quantities can be normalized with respect to the baseline
values (Fig. 1-D), correcting for the intrinsic initial variability of the
animals assigned to different groups (Glatt et al., 2007; Silva et al.,
2012).
With voxel sizes down to 9 m,  this technique can measure
efﬁciently the size and distribution of small bone features such as
trabeculae. Moreover, once applied to the mouse, the whole verte-
brae (Lambers et al., 2012; Schulte et al., 2011) and long bones (Lu
et al., 2015a) can be scanned, guaranteeing more comprehensive
analyses in those speciﬁc anatomical sites.
2.2.2. Applications for mineralized tissues
In vivo micro-CT has been already used in mice to study the effect
on the bone microarchitecture and density of musculoskeletal
pathologies related to ageing such as osteoporosis (Klinck and Boyd,
2008), fractures (He et al., 2011) and bone metastases (Ravoori et al.,
2010). Furthermore, this technique has been used for studying the
effect of pharmacological treatments (Stadelmann et al., 2011) and
of external loading (Silva et al., 2012; Willie et al., 2013) on calci-
ﬁed (hard) tissues. In particular, Klinck and Boyd (2008) used in vivo
micro-CT scans of the proximal tibia for assessing the magnitude of
bone changes due to ovariectomy in different inbred mice strains,
in order to select the best mouse model of accelerated bone loss. In
two other studies, Silva et al. (2012) and Willie et al. (2013) investi-
gated the effect of in vivo mechanical loading of the mouse tibia on
the related longitudinal bone changes in the trabecular and corti-
cal compartments, in function of ageing. Similarly, Stadelmann et al.
(2011) studied the effect of combined in vivo loading and injections
of zoledronate on the properties of the cortical bone of the mouse
tibia. Furthermore, He et al. (2011) have used in vivo micro-CT to
investigate bone healing in a defect-induced mouse femur model,
showing the defect-closing rate on the same animals tracked over
time. Ravoori et al. (2010) showed how induced prostate cancer
affects the bone mineral density in a mouse model by using low res-
olution in vivo micro-CT. Moreover, if coupled with advanced image
processing techniques, such as image registration, in-vivo micro-CT
imaging can improve the precision of bone parameter measure-
ments, therefore increasing the sensitivity to detect changes in the
bone micro-architecture following intervention (Baiker et al., 2011;
Campbell et al., 2014). This technique can also provide low resolu-
tion scans of the whole skeleton (Fig. 1-C1) and high resolution
scans of the whole bones in vivo (Fig. 1-C2,C3,C4), and allows users
to generate subject speciﬁc computational models for non-invasive
estimation of bone strength as well as local mechanical properties
associated with ageing (Lambers et al., 2012, 2015; Razi et al., 2015)
or different interventions (Levchuk et al., 2014; Willie et al., 2013;
Yang et al., 2014).
2.2.3. Applications for soft tissues
Although bone imaging is the most common in vivo micro-CT
application, increasing evidence shows that non-mineralized (soft)
tissues can also be imaged, provided there is sufﬁcient contrast
between the tissue of interest and the surrounding areas (Bouxsein
et al., 2010). These methods allow micro-CT to be used for the study
of some soft tissues related to pathologies such as, for example,
osteoarthritis, atherosclerosis and lung tumours. Many soft tissues
have been scanned ex vivo with or without contrast agents: soft tis-
sue of the paw (Perilli et al., 2015), angiogenesis (Gayetskyy et al.,
2014) and cartilage (Marenzana et al., 2014) are examples. How-
ever, only a few of these procedures are applicable in vivo. One
approach is to use the intrinsic heterogeneity of the native contrast
that some tissues possess, as for lung imaging or adipose tissue. For
example, the lung tissue has the particularity of presenting a good
contrast with the air it is ﬁlled with. In vivo lung imaging, com-
bined with custom image processing algorithms, provides a good
tool to study lung function in acute and chronic small animal pul-
96
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Table 1
Summary of the speciﬁcations, main advantages and main limitations of the preclinical in vivo imaging techniques presented in this review, with particular emphasis on the applications for studying ageing or age-related diseases
with  mouse models.
Preclinical
In vivo imaging
modality
Imaging Time Maximal resolution Advantages Disadvantages Main Longitudinal applications
associated to ageing and
age-related diseases
Examples
Micro CT min-h ∼0.01 mm (organ)
∼0.1 mm (body)
Very good spatial resolution
Good sensitivity
Long scanning time
Potential moving artifacts
Radiation exposure
Limited number of contrast
agents for in vivo applications
Osteoporosis and remodeling
Bone metastasis
Neurodegenerative diseases
Lung and liver tumour
progression
Bone regeneration (combined
with SPECT)
Klinck and Boyd (2008); Silva et al.,
(2012); Willie et al. (2013)
Ravoori et al. (2010)
Starosolski et al. (2015)
Lalwani et al. (2013)
Ohta et al. (2006)
He  et al. (2011);
Lienemann et al. (2015)
Micro MRI min-h ∼0.1 mm
(in plane)
Good spatial resolution
Contrast agents can be used
Long scanning time
Potential moving artifacts
Poor sensitivity (can be
improved with contrast agents)
Alzheimer’s disease
Cardiac structure and function
Decreased brain function
Maheswaran et al. (2009)
Schneider et al. (2008)
Sorond et al. (2011)
PET min  ∼1 mm High sensitivity
Many radiotracers
Poor spatial resolution
Requires specialized
radiochemistry
Radiation exposure
Alzheimer’s disease
Parkinson’s disease
Atherosclerosis
Type 2 diabetes
Fodero-Tavoletti et al. (2011)
Waerzeggers et al. (2010)
Wenning et al. (2014)
Yong et al. (2011)
SPECT min  ∼1 mm Good sensitivity (lower than
PET)
Fewer radiochemicals
compared to PET
Radiation exposure
Parkinson’s disease
Alzheimer’s disease
Oncology
Bone regeneration (combined
with microCT)
Hwang et al. (2002)
Shimizu et al. (2016)
Bernsen et al. (2014)
Lienemann et al. (2015)
Ultrasound s 0.5 mm (3 MHz)
0.15 mm  (10 MHz)
Great temporal resolution.
Portable
no long-term side effects
Relatively cheap
Poor depth-of-ﬁeld for high
resolution imaging (high
frequency).
Poor bone and air penetration.
The method is
operator-dependent
Liver diseases
Cardiac ﬁbrosis
Hydronephrosis
Fernandez-Dominguez et al. (2011)
Johnson et al. (2013)
Springer et al. (2014)
Optical
intravital
microscopy
s <0.01 mm Real time imaging
Very high resolution
Good sensitivity
Many contrast agents
Relatively cheap
2D technique requires surgery Cortical plasticity
Beating heart
Atherosclerosis and myocardial
infarction
Stodieck et al. (2014)
Vinegoni et al. (2015)
Swirski and Nahrendorf (2013)
Whole body
optical imaging
s-min ∼0.1 mm (organ)
∼1 mm (body)
High sensitivity
Many ﬂuorescent markers
available
Relatively cheap
In most cases still 2D technique
Requires genetically modiﬁed
tumour cells
Nude or shaved animals
required
Alzheimer’s disease
Diabetes, Hypertension
Osteoarthritis
Tumour vasculature
Lin et al. (2014)
Hall et al. (2012)
Lai et al. (2004)
Pesnel et al. (2012)
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Fig. 1. Examples for in vivo micro-CT imaging: A) The Scanco Viva80 is an example of a commercially available in vivo micro-CT (courtesy of Scanco Medical AG). B) Particular
of  the scanning area and of the mouse holder with the sensors used to monitor the mouse status during the scan. Different images can be obtained with this system for
analyses of bones: C1, low resolution scan and 3D reconstruction of the whole mouse skeleton and soft tissues. Scans were performed with 71.8 m voxel size, 55 KeV voltage,
145  A current, and 20 ms  integration time; C2, high resolution scan and 3D reconstruction of the whole mouse tibia. Scans were performed with 10.4 m voxel size, 55 KeV
voltage, 145 A current, and 200 ms  integration time; C3-4, Cross sections of the reconstructed trabecular and cortical regions from C2. D: Example of analyses of longitudinal
changes in trabecular bone volume fraction (BV/TV) with respect to baseline (week 0) with scans performed every week for ovariectomized (Ovx, N = 7) and sham operated
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pSham, N = 4) 14 weeks old C57BL/6J female mice (unpublished data).
onary disease models when combined with respiratory gating
Artaechevarria et al., 2009; Johnson, 2007). This method can also
e applied for monitoring the progression of lung tumours (Li et al.,
013; Rodt et al., 2009). Moreover, in vivo imaging of adipose tissue
sing micro-CT provides more details compared to 2D dual energy
-ray absorptiometry (DXA) and was found to be as accurate yet
ore cost and time effective than preclinical-MRI in assessing body
omposition and discriminating between adipose and non-adipose
issue (Luu et al., 2009; Wyatt et al., 2015). Another approach to
isualize the target tissue is the use of contrast agents (Lusic and
rinstaff, 2013). For instance, in vivo contrast-enhanced micro-CT
as been used to monitor liver tumours progression (Ohta et al.,
006), to evaluate rodent models of hepatic/brain ischemia and
troke (Hayasaka et al., 2012), to evaluate cartilage degeneration
n rats (Piscaer et al., 2008), and to quantify vasculature in mice
Nebuloni et al., 2014; Starosolski et al., 2015). Finally, nanopar-
icles as contrast agents were used in an in vivo micro-CT setting
o monitor tumour vasculature (Ghaghada et al., 2011), and the
rogression of lung tumours (Lalwani et al., 2013).2.2.4. Summary of advantages and limitations
The main advantage of in vivo micro-CT imaging is the high
penetration depth of X-rays through the different tissues, which
leads to the high image resolution (voxel size down to 8–10 m),
enabling accurate longitudinal measurements of anatomical fea-
tures, of bone or stained soft tissues. The great potential of in vivo
micro-CT is also its ability to be coupled with other in vivo imag-
ing modalities such as preclinical-PET in order to evaluate for
example carcinogenesis and treatment strategies in circumscribed
lung tumours (Rodt et al., 2009), and optical imaging to monitor
for example the dynamic changes in bacterial burden, neutrophil
recruitment and bone damage in a mouse orthopaedic implant
infection model (Niska et al., 2012). More details about these tech-
niques will be provided in the next sections.
Despite its advantages, in vivo micro-CT imaging has a num-
ber of limitations. First, being an X-ray based imaging modality;
the associated radiation dose to which the animal is exposed dur-
ing scanning is an important factor to consider as it could affect
the measurements. Several studies have assessed the impact of
successive imaging on the organ or tissue integrity and function.
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t appears that the radiation affects differently soft and hard tis-
ues and a number of studies have been performed to reach the
est compromise between image quality and radiation dose (Klinck
nd Boyd, 2008; Laperre et al., 2011; Vande Velde et al., 2015).
owever, there is not yet general consensus about standardized
canning protocols for the different anatomical sites and there is
o way to estimate the effective radiation dose (i.e. the tissue-
eighted sum of the equivalent radiation dose in all tissues and
rgans of the body during the scan) in the mouse. Consequently,
n order to reduce the scanning time and therefore the radiation
ose, in vivo analyses are usually performed with lower resolution
9–15 m for bone) compared to ex vivo imaging (down to 1–5 m
or bone), with a resulting decreased precision when measuring
mall features of mouse bones (e.g. average trabecular thickness in
he proximal tibia is approximately 40–60 m).  A second limita-
ion is related to motion artifacts: with micron level resolutions,
ny movement of the animal while under anaesthesia will lead to
otion artifacts on the acquired images. To minimize them, spe-
ial holders are provided by the manufacturers to ensure the target
rgan/tissue is well placed and maintained. However, they cannot
e completely removed in particular when central sites (e.g verte-
rae, lungs) are scanned. Additionally, animal wellbeing must be
onitored at all times, increasing the complexity of the scan and
he costs associated with it. Under general anaesthesia, mice are
nable to maintain normothermia (with a drop in core tempera-
ure of 1 ◦C every 4 min  for a C57Bl6 mouse) (Caro et al., 2013). It
s therefore imperative to add a heating system in order to main-
ain the animal’s temperature as close as possible to normothermia.
reathing pattern should also be monitored carefully, to minimize
ny discomfort to the animal, but also to minimize the risk of move-
ent artifact (gasping, unsteady breathing pattern). When properly
onitored, a mouse can be maintained under anaesthesia for up to
 h, with fast recovery and no apparent short term effect (Lu et al.,
015a).
.3. Preclinical magnetic resonance imaging (MRI)
.3.1. Technique
Magnetic resonance imaging (MRI) utilises a strong magnetic
eld to polarise the magnetic moments of speciﬁc nuclei within the
ubject. This generates a signiﬁcant equilibrium net magnetisation.
adio frequency coils are used to transmit short electromagnetic
ulses to perturb this magnetisation. As the magnetisation relaxes
ack to the equilibrium position a decaying oscillatory electrical
urrent is induced in the radio frequency antennae. To spatially
ocalise the signal in three dimensions, powerful magnetic gradi-
nt coils are used to encode these oscillating signals in terms of
heir frequency and phase. These electrical signals are interpreted
via Fourier transform) into an image with different tissues having
ifferent signal amplitudes and decay rates. The amplitude of the
ignal is primarily affected by the nuclei density within the tissue.
he decay rate is indicative of two different physical effects; i) the
ransfer of energy from the nuclear spin system to adjoining/lattice
olecules and ii) the loss of phase of the oscillatory signal caused
y magnetic ﬁeld in-homogeneities and direct interaction between
uclei (without energy loss to the surrounding lattice). As such MRI
as unparalleled soft tissue contrast and is now widely used in age
elated research in both human and animal studies. For a more
etailed description of MR  theory the reader should consult the
xisting literature [1–4].
Preclinical-MRI is an ideal technique for the investigation of sev-
ral age related disease phenotypes; the main advantages being
hat it offers in-vivo,  high resolution, 3D, non-invasive images. The
atter importantly permits longitudinal studies using knockout and
ontrol mice, a prerequisite for advancing age related research.
urthermore, the preclinical-MRI technology used in the preclin-d Development 160 (2016) 93–116
ical setting is identical to that already used in hospitals worldwide
for diagnostic purposes but often provides smaller bore holes and
higher magnetic ﬁeld strength. This means that promising new in
vivo biomarkers or treatment strategies involving preclinical-MRI,
for age related disease phenotypes, have the potential for direct
clinical translation.
2.3.2. Most common applications
The most commonly imaged nuclei in biological organisms are
the hydrogen protons contained within the abundant water pool.
The brain and heart (the most commonly imaged organs with MRI)
are composed of 73% water. Other tissues that are associated with
age related diseases, e.g. the muscles and kidneys are composed of
79% water (Mitchell et al., 1945). By imaging such tissues over time,
development of solid organ atrophy and other phenotypes can be
detected throughout the body. Since age is a major risk factor for
neurodegenerative disease, MRI  has been used extensively to mon-
itor structural changes within the brain, comparing pathological
measurements to normal age related changes.
Clinical MRI  studies have shown that the brain decreases in
total volume at an accelerated rate after the age of 50 (Craik and
Salthouse, 2000; Raz et al., 2005; Raz and Rodrigue, 2006) and vol-
umetric analyses with MRI  is actively used in the diagnosis of mild
cognitive impairment and Alzheimer’s disease; with an impressive
diagnostic accuracy of approximately 90% (Norfray and Provenzale,
2004). MRI  technology has also shown that white matter changes
are an effect of very old age (Raz et al., 2005; Salat et al., 1999;
Sowell et al., 2003) whereas grey matter loss starts earlier and is
more gradual.
These gross structural changes have been replicated in nor-
mal  and transgenic mice used in ageing studies, using high ﬁeld
MRI  (>7 T) that is commonly used in the pre-clinical setting
(Maheswaran et al., 2009). Although simple structural MRI alone
cannot deﬁne the causal pathway of these changes, it can help con-
ﬁrm that new mouse models of ageing and associated diseases are
displaying the required pathology. Even though volumetric brain
analysis appears to be a suitable metric of age related changes,
the power of MRI  really shines through when it is used in con-
junction with other pre-clinical techniques. For example animal
studies with electrophysiology and calcium dye imaging (Burke and
Barnes, 2006) have provided evidence that deﬁcit in brain plastic-
ity (its ability to form new connections and memories) is a result
of age induced changes in calcium regulation. Changes in calcium
regulation directly affect action potentials as they traverse axons
and thus change neuronal pathways. For a full review the reader is
referred to Burke and Barnes (2006).
MRI  also has the potential for identifying such breakdowns in
cerebral networks directly, beyond measurements of gross struc-
tural deﬁcits. Diffusion tensor imaging (DTI) gives a measure of
the magnitude and orientation of the diffusion of water (the stan-
dard proton signal source). With no barriers, water is free to move
in any direction, diffusing isotropically. However the brain is full
of long neuronal bundles, which constrain the movement of the
water so that it tends to follow the long axis of the bundles (result-
ing in anisotropic diffusion). DTI-MRI measures the strength of the
directional dependence of diffusion and therefore to some extent
tissue disruption, the so-called fractional anisotropy (FA). If the
neuronal bundles are disrupted the molecular motion will return
to its free diffusion state and lead to decreased FA. Studies using
DTI-MRI FA metrics suggest that the microstructure of the white
matter integrity is different between normal and pathological age-
ing (Minoshima and Cross, 2008; Song et al., 2004). However, like
structural MRI  there is no global standard for DTI analysis, which
can drive over interpretation of results. It is in the end only mea-
suring diffusion driven by axonal membrane integrity with myelin
playing a modulatory role (Beaulieu, 2002).
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Fig. 2. BOLD fMRI is a very qualitative and pseudo measure of neuronal activity. Only by combing fMRI with other neuro-imaging techniques can one really understand
neurovascular coupling. Concurrent fMRI and optical imaging can be used to investigate changes in the brain’s vascular response with age in rats (Kennerley et al., 2012).
BOLD  fMRI statistical activation maps in this topographic plane can be compared directly to complementary functional haemodynamic statistical maps from 2D-OIS. The
underlying micro-vasculature can be identiﬁed using optical imaging both inside the magnet and outside (without the endoscope).
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A surrogate measure of neuronal activity can be made using
unctional MRI  (fMRI). fMRI relies on a process known as neurovas-
ular coupling, where localised changes in neuronal activity drive
hanges in vessel diameter in order to control cerebral blood ﬂow
nd to supply the required substrates to that region of the brain. The
issue is often hyper-perfused which leads to an overall increase
n cerebral blood oxygenation, making the relative percentage
f paramagnetic deoxyhaemoglobin lower. This homogenises the
ocal magnetic ﬁeld and results in an increase in MR  signal mag-
itude – the so-called Blood Oxygenation Level Dependent (BOLD)
MRI signal (Kwong et al., 1992; Ogawa et al., 1990). Studies using
his technique in rats have shown a change in the brain’s vascular
esponse with age (Dubeau et al., 2011). Subsequent breakdowns
n neurovascular coupling can lead to decreased function (Sorond
t al., 2011). BOLD fMRI by itself is a very qualitative measure and
nly a pseudo-measure of neuronal activity. In order to investi-
ate if neuronal pathways break down and drive smaller changes in
he haemodynamics or if the vascular disruption limits delivery ofmetabolites and cause cell death (Zlokovic, 2010), BOLD fMRI needs
to be coupled with other neuro-imaging techniques such as optical
imaging spectroscopy (Kennerley et al., 2012) (Fig. 2) and electro-
physiology (Pan et al., 2010). This coupling provides measurements
of changes in the haemodynamic response and neuronal response
respectively in animal models.
Following the vascular hypothesis for neurovascular coupling
breakdown as a mechanism of decreased cognitive function and
development of neurodegenerative diseases, one could make a
causal link from early age cerebral hypo-perfusion and vascular
risk factors leading to white matter damage (Firbank et al., 2007;
Spilt et al., 2005). Recent studies have attempted to elucidate the
relationship between brain perfusion variability and risk factors of
endothelial dysfunction and atherosclerosis in healthy aged sub-
jects (Henriksen et al., 2014). It was concluded that the amino acid
homocysteine, increased amounts of which make a person more
prone to endothelial cell injury and thus blood vessel inﬂammation,
may  be a marker of cerebral perfusion in ageing brains. Magnetic
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esonance angiograms, where stationary tissue contrast is nulled
nd only signal from ﬂowing blood measured, could ﬁnd use in the
ssessment of such effects (Beckmann et al., 2003; Slawson et al.,
998; Wiesmann et al., 2002, 2000).
Not only hydrogen nuclei in water but also nuclei in other
olecules/metabolites exhibit magnetic resonance. This opens up
he possibility of studying ageing effects on cellular metabolism in
ifferent organs. Importantly, the resonance frequency is different
or each metabolite, which can therefore act as a ﬁnger-print of
he relative concentrations of different target metabolites (Rudin,
992), once the water signal is nulled. Magnetic resonance spec-
roscopy (MRS) predates MRI, and as an analytical technique has
een applied to studies of ageing in human (Robertson et al.,
001) and in mice (Oberg et al., 2008; Yang et al., 2011). More-
ver, Carbon-13 MRS  can be used for characterising ﬂuxes and
athways of metabolism. Using Phosphorus-31 MRS  one can inves-
igate adenosine tri-phosphate synthesis directly (Pettegrew et al.,
987). The problem is that these nuclei have low abundance in the
ody and therefore signals are difﬁcult to measure. A new tech-
ique involving hyperpolarisation of carbon-13 labelled metabolic
ubstrates, which can increase their MR  signal by 10,000 times
Ardenkjaer-Larsen et al., 2003), has started a resurgence in the ﬁeld
f MRS. This technique has been used mainly for cancer research,
ut it has also been applied to investigate cardiac metabolism
Aquaro et al., 2013) – dysfunction of which is related to the ageing
rain.
.3.3. Summary of advantages and limitations
Preclinical-MRI is an ideal technique for the investigation
f several age-related disease phenotypes; the main advan-
ages being that it offers in-vivo,  relatively high resolution, 3D,
on-invasive images. The latter importantly permits longitudi-
al studies using knockout and control mice, a prerequisite for
dvancing age related research. Furthermore, this technique is very
imilar to its clinical counterpart, making the clinical translation
traightforward.
Limitations of MRI  are the inherent low sensitivity and, due to
he size of the mouse compared to the human, the need for high
eld strength systems for pre-clinical studies. Most pre-clinical
RI  centres employ MRI  systems with ﬁeld strengths of 7 T and
bove. The high ﬁeld increases the nuclear magnetic polarisation
nd therefore the signal; in turn this can be sacriﬁced to increase
he spatial resolution to achieve a good standard in the pre-clinical
odel. The small size of the mouse also necessitates the use of
tronger imaging gradients (typically around 300+ mT/m in mice
ompared to 30+ mT/m in human) to enable to system to achieve
hese higher resolutions. In essence, both clinical and preclinical
ystems are superconducting solenoids surrounded by a helium
ryostat. Preclinical systems only differ in their reduced bore size
to make the engineering of the higher ﬁelds and gradients easier).
ith this advanced/miniaturised technology comes a hefty price
ag with pre-clinical MRI  systems often on a par with their clini-
al counterparts. It might be naively presumed that the higher the
eld strength, the better for mouse imaging. However, although
he polarisation (and hence signal) increases, the ﬁeld becomes
ncreasingly more difﬁcult to homogenise (images appear dis-
orted) and the relaxation times of the MR  signal decrease with
ncreased ﬁeld strength. This means that image contrast changes
nd data must be captured in shorter echo time periods (Duyn,
012). The choice of ﬁeld strength must always be informed by
he proposed application. For example, a reduced ﬁeld strength is
dvised for imaging the pulmonary system to ensure relaxation
imes are long enough to capture data. For functional MRI, ﬁeld
trengths around 7–9.4 T are optimal for a balance between signal
nd image distortions with fast echo planar imaging. For these rea-
ons, low ﬁeld strength (<7 T) benchtop permanent magnet imagingd Development 160 (2016) 93–116
systems are becoming common-place to complement high ﬁeld
superconducting systems. These are cheaper, smaller and do not
require expensive cryogenics or cooling systems. For this reason,
as this technique develops, one might see a separation of clinical
and preclinical-MRI techniques – whether this be an advantage or
disadvantage remains to be seen. There are also other limitations
related to the handling of living animals during the scanning pro-
tocol, especially within the very small bores of high ﬁeld strength
systems. The animal is usually anaesthetised by using gaseous
isoﬂurane, levels of which are incredibly difﬁcult to stabilise when
all monitoring equipment has to be non-magnetic and by neces-
sity is viewed remotely outside the scanner room. Breathing rate
is often the only metric one has to assess the levels and this can
change rapidly in a mouse. It can also be a challenge to keep the
animals warm within the cold bore of a superconducting magnet.
Different centres have very different strategies, employing hot air,
heating blankets or water based systems, sometimes without tem-
perature control feedback. Any slight changes in basic physiology
(which could also be different between knockout groups and con-
trols) could be a major contributing factor in result variation and
can be incredibly to control for. Schneider et al. (2008) attempted
to use cine-MRI for determining global cardiac function longitudi-
nally in guanidinoacetate N-methyltransferase (GAMT) knockout,
and wild type littermate mice. They soundly hypothesized that lack
of creatine in GAMT knockouts would be detrimental for resting
cardiac performance during ageing. However, they found no phys-
iologically signiﬁcant differences in cardiac function between wild
type and GAMT knockout mice at any time point, perhaps reﬂect-
ing some comprehensive adaptation in the knockouts to account
for lack of creatine or again that changes in physiology masked
the results. Although perhaps a perplexing negative result, the
study was the ﬁrst to report on the longitudinal investigation of
a transgenic mouse model using cardiac MRI  over the period of
one year. This application demonstrates the power of the technique
to accurately quantify cardiac functional parameters in genetically
modiﬁed mice in a longitudinal fashion and start to address the link
between cardiac and brain ageing.
2.4. Preclinical positron emission tomography (preclinical-PET)
2.4.1. Technique
Positron emission tomography (PET) can visualize the distribu-
tion and concentration of radiolabelled molecules injected into the
subject and can be used to monitor, in vivo, biological processes
such as enzymatic reactions, cellular metabolism, cell proliferation
and migration (Phelps, 2000). Its preclinical version is a potent
imaging modality for the investigation of age related diseases
in vivo in mouse models. PET offers a high sensitivity and speciﬁcity
for most imaging applications.
The spatial resolution of preclinical PET systems should ideally
compensate for the smaller organ sizes in mouse models compared
to humans. Thanks to advances in light detector technology, sys-
tems with spatial resolutions in the order of 1.5 mm to 1.6 mm
(Balcerzyk et al., 2009; Bao et al., 2009) and below, some resolving
structures smaller than 1 mm in size (Bergeron et al., 2014; Nagy
et al., 2013), are now commercially available. It is even possible to
resolve structures as small as 0.7–0.8 mm using some research sys-
tems (Espan˜a et al., 2014; Weissler et al., 2015). However, this is
still a relatively low resolution when considering the small size of
mice. Unfortunately, time-of-ﬂight PET (ToF-PET) does not signif-
icantly improve the image quality of preclinical imaging directly,
but a good timing resolution still allows users to reduce the random
coincidences rate (Strother et al., 1990). Recently, ToF-PET beneﬁts
were imaged for phantom diameters equivalent to the size of a rab-
bit on a research system with a timing resolution of about 260 ps but
could not be shown for mouse-sized activity distributions (Schug
ing an
e
r
m
p
c
f
j
i
i
r
c
e
m
f
o
a
c
2
A
l
w
m
b
e
p
m
2
p
p
p
i
(
2
d
l
a
(
r
u
E
a
i
s
b
u
p
b
w
p
n
e
2
a
s
o
o
ﬁE. Dall’Ara et al. / Mechanisms of Age
t al., 2015a), that would need a further improvement of timing
esolution (below 100 ps).
As most PET tracers only allow acquisition of functional infor-
ation, PET is often combined with a second imaging modality to
rovide an anatomical reference image. The combination of PET and
omputed tomography (CT) is commonly used in clinics as well as
or preclinical applications. Here, the two modalities image the sub-
ect sequentially and not at the same time (Fig. 3A). PET integrated
nto an MRI  system, on the other hand, offers real simultaneous
mage acquisition allowing for excellent spatial as well as tempo-
al co-registration if the interference between the two modalities
an be reduced to an acceptable level (Schug et al., 2015b; Wehner
t al., 2015; Weissler et al., 2015) (Fig. 3B).
Many age related diseases can be studied with the help of mouse
odels. We  discuss a few of the most common diseases with
ocus on the PET imaging possibilities and challenges. Examples
f prominent diseases are picked from the ﬁelds of neurodegener-
tive, cardiovascular, and metabolic diseases and cancer without
laiming to give a full overview.
.4.2. Neurodegenerative diseases
Dementia is a disease strongly related to ageing with
lzheimer’s disease (AD) being the most common form. The patho-
ogical features in the AD brain include amyloid- (A)  plaques
hich can be imaged with PET (Nordberg, 2004). An established
ethod for in vivo evaluation of A-plaque burden in the human
rain is PET using the Pittsburgh compound-B (PiB) (Ikonomovic
t al., 2008; Klunk et al., 2004). Recent technical improvements in
reclinical PET systems allowed a successful translation to mouse
odels, including a gain in spatial resolution (Manook et al.,
012) (Fig. 3C). Besides imaging of A plaques, tau is a further
romising target in early AD diagnosis. Neuroﬁbrillary tangles are
rimary markers of AD and represent aggregates of the hyper-
hosphorylated tau protein. A novel tau-targeting PET radiotracer
s [18F]THK523 has shown very promising results in preclinical
Fodero-Tavoletti et al., 2011) and clinical studies (Okamura et al.,
014).
Parkinson’s disease (PD) is another common neurodegenerative
isorder related to ageing, mainly affecting the motor system. In
ater stages of the disease, thinking and behavioural problems may
rise. PD has been investigated in toxin-induced and genetic models
Bové et al., 2005; Fleming et al., 2005; Melrose et al., 2006). Using
ecent preclinical PET systems it has become feasible to study PD
sing [18F]DOPA in vivo in e.g. weaver mutant mice (Sharma and
badi, 2005; Waerzeggers et al., 2010).
In general, for detailed investigations of neurological activity
nd diseases using preclinical PET the spatial resolution of the
mage is a crucial performance parameter. With state-of-the-art
ystems it is possible to resolve individual regions of the mouse
rain which enables e.g. the imaging of changes in brain activity
sing [18F]ﬂuorodeoxyglucose (FDG).
For multimodal imaging of neurodegenerative diseases,
reclinical-PET and preclinical-MRI is the preferred combination
ecause preclinical-MRI provides an anatomic reference image
ith excellent soft-tissue contrast to morphologically describe the
athologic alterations and also allows measuring their impact on
euronal activity and connectivity (Jack et al., 2010; Logothetis
t al., 2001).
.4.3. Cardiovascular diseases
Atherosclerosis is a chronic age related disease that remains
symptomatic for decades and is the principal cause of heart attack,
troke and gangrene of the extremities and responsible for 50%
f all mortality in the USA, Europe and Japan (Ross, 1993). It is
ften caused by high-risk plaques whose features may  show a thin
brous cap, large necrotic core, macrophage inﬁltration, neovascu-d Development 160 (2016) 93–116 101
larization, and intraplaque hemorrhage (Owen et al., 2011). In the
clinic, several of these features can be investigated using PET. For
example, FDG is often used to identify inﬂammatory plaques rich
in macrophages (Rudd et al., 2002; Tawakol et al., 2006).
A wide range of animal models for atherosclerosis research
is available (Kapourchali et al., 2014). In general, they are most
useful to investigate the aforementioned features of plaques but
not so much to model the complications of atherosclerosis, such
as rupture and thrombosis (Cullen et al., 2003). While FDG PET
was used to study atherosclerosis in rabbits (Nie et al., 2016)
in order to predict plaque rupture (Aziz et al., 2008), mice have
to be genetically modiﬁed in order to develop atherosclerosis at
all because of a very different fat metabolism. Most common is
the transgenic ApoE deﬁcient mouse model, where mice develop
plaques in dependence of their diet. In this model plaque rup-
ture can be triggered by surgical ligation of the brachiocephalic
or carotid artery (Hartwig et al., 2015; Matoba et al., 2013). Using
ApoE deﬁcient mice, it could be shown that FDG-PET is able to
distinguish shear-stress induced, inﬂamed atherosclerotic plaques
from non-inﬂamed plaques in vivo (Cheng et al., 2006; Wenning
et al., 2014). An even more accurate characterization of the inﬂam-
mation status in plaques may  be enabled using, amongst others,
the macrophage targeted probes [64Cu]TNP (Nahrendorf et al.,
2008) or (LyP-1)4-dendrimer-64Cu (Seo et al., 2014), the scavenger
receptor targeted probe 64Cu-CD68-Fc (Bigalke et al., 2014), 64Cu-
DOTA-vMIP-II binding to viral macrophage inﬂammatory protein
II (vMIP-II) (Liu et al., 2013) and the v3 integrin-targeted tracer
18F-galacto-RGD (Laitinen et al., 2009; Saraste et al., 2012).
2.4.4. Metabolic diseases
Diabetes mellitus (DM) type 1 is caused by a loss of the insulin-
producing -cells, which are found in the pancreatic islets. DM
type 2 on the other hand is characterized by insulin resistance.
PET is often used to image the -cell mass and number which
is challenging in mice in vivo because of the small dimensions
of the pancreas and the spotted location and considerably low
number of pancreatic islets. Furthermore, the pancreas is located
close to the kidney, which is the excretion organ of most PET
probes. Therefore, there is high demand for high spatial resolu-
tion to separate signals from both organs. Nonetheless, PET imaging
using [18F]ﬂuorohydroxymethyl-butyl-guanine (FHBG) is sensitive
to changes in -cell mass that precede the onset of diabetes (McGirr
et al., 2011). This has been shown in mouse models of diabetes type
1 and type 2 expressing multi-modality reporters for ﬂuorescence
microscopy and in vivo bioluminescence imaging in their -cells.
These models nicely conﬁrmed that the FHBG PET signal strongly
correlates with the -cell number and mass (Yong et al., 2011).
2.4.5. Tumours
The most frequent deadly disease related to ageing is cancer.
With a higher age of the patient or animal, increasing instability of
the genome, decreased activity of the immune system and accu-
mulated environmental inﬂuences lead to a higher probability of
developing tumours.
As a quantitative whole body imaging modality and due to the
availability of excellent radiotracers PET is ideally suited for the
imaging of cancer, both for clinical and preclinical applications
(Gambhir, 2002). Multiple tracers have been used to study glucose
metabolism ([18F]FDG), amino acid ([11C]methionine) and choline
([11C]choline) uptake, cell proliferation ([18F]FLT), inﬂammation
([18F]Galacto-RGD) and hypoxia ([18F]MISO). Among those FDG is
the most widely used radiotracer, because it is readily available
and has been shown to work effectively due to the high glu-
cose consumption of most malignant tumour cells (Vander Heiden
et al., 2009). Besides these purely diagnostic radiotracers targeting
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Fig. 3. Examples for preclinical hybrid PET imaging devices are shown in A and B:.
A:  The nanoScan® SPECT/CT/PET is an example of a commercially available multi-modality preclinical imaging device (©MEDISO Medical Imaging Systems, courtesy of
MEDISO).
B:  The PET/MRI research insert “Hyperion-IID” is shown mounted on a standard patient table of a clinical 3T MRI  system (gantry cover removed). The system allows real
simultaneous image acquisition with both modalities (Adapted and reprinted from (Weissler et al., 2015)). Examples for PET imaging of mice with neurodegenerative and
oncologic diseases are shown in C and D:
C: Alzheimer’s disease imaging in a mouse showing A-positive plaques in vivo and ex vivo. PET images are acquired with the tracer [11C]PiB. Corresponding autoradiography
and  ﬂuorescence microscopy images conﬁrm PiB binding to plaque sites.
C1: [11C]PiB PET image. The low resolution of PET does not allow identiﬁcation of individual plaque sites but larger affected brain regions can be seen. The width of color
scale  represents 3 mm in reality.
ing an
m
a
t
a
t
m
k
a
a
e
a
I
s
p
m
l
n
s
r
u
g
P
2
i
t
p
P
t
h
O
i
1
p
2
2
t
s
e
m
h
t
h
i
h
b
l
m
s
f
m
C
w
C
m
T
D
w
t
e
c
fE. Dall’Ara et al. / Mechanisms of Age
ore general tumour mechanisms, there are radiotracers which
re very closely linked to therapy and act as companion diagnos-
ics and theranostics. For example, the majority of lung cancers
re non-small-cell lung cancers (NSCLC) which are difﬁcult to
reat. A small subset of NSCLC express mutations of the epider-
al  growth factor receptor (EGFR), which are sensitive to tyrosine
inase inhibitors, such as erlotinib (Wu  et al., 2012). Thus, there is
 demand for methods to select these patients for erlotinib ther-
py and to exclude those who do not express EGFR. This is an
xcellent example for the indication of personalized therapy and
 motivation to develop companion diagnostics and theranostics.
n this context, the PET tracer [11C]-erlotinib was developed and
uccessfully evaluated in mouse models of lung cancer overex-
ressing EGFR (Li et al., 2007; Memon  et al., 2009). However, in
ouse models the strong accumulation of [11C]-erlotinib in the
iver sometimes made it difﬁcult to identify basal lung cancer sig-
als due to spillover effects especially on PET systems with a low
patial resolution. As another example, older age is one of the main
isk factors for prostate cancer. A wide range of mouse models is
sed in prostate cancer research including xenograft and trans-
enic mouse models (Ittmann et al., 2013). For visualization with
ET, an 18F-labeled choline analogue ([18F]ﬂuoromethyl-dimethyl-
-hydroxyethyl-ammonium (FCH)) was successfully applied both
n humans and mouse models (DeGrado et al., 2000). Even bet-
er results were obtained with recent PET-radiotracers targeting
rostate speciﬁc membrane antigen (PSMA). Of those 68Ga-labelled
SMA showed excellent binding properties in mice bearing LNCaP
umour xenograft (Schäfer et al., 2012) (Fig. 3D) as well as in
umans where it proved to be superior to choline tracers (Afshar-
romieh et al., 2014). A further advantage of this compound
s that 68Ga can be replaced by the therapeutic radioisotope
77Lu and initial results in tumour bearing mice as well as in
atients show promising therapeutic outcomes (Kratochwil et al.,
015).
.4.6. Summary of advantages and limitations
Preclinical-PET imaging of mouse models is highly valuable for
he investigation of age related diseases as it offers high sensitivity,
peciﬁcity and a wide range of available tracers for various dis-
ase ﬁelds as for example neurodegenerative, cardiovascular, and
etabolic diseases and cancer (see Table 2 for a selective overview).
The limiting factor of investigating mice with PET is, besides the
igh cost and the handling with (sometimes fast decaying) radioac-
ive material, mainly the low spatial resolution which, however,
as seen constant improvement over the last years. In addition,
ts limitations in anatomical information can be compensated by
ybridizing PET with CT or MRI. Finally, animal handling has a
ig impact on the metabolism of a mouse and FDG performed in
iver, brain and other organs can strongly vary dependent on the
etabolic state, activity and temperature of the animal. Anaesthe-
ia of animals should also be considered. Isoﬂurane is well suited
or tumour-bearing mice. Ketamine/xylazine, on the other hand,
ay  induce hyperglycemia (Fueger et al., 2006).
2: Digital [3H]PiB ex vivo autoradiograph showing the PiB binding sites in high-resolutio
ith  double immunoﬂuorescence microscopy of A40 (green) and A42 (red) in C3 and 
5–7:  Identical A plaque constellations of adjacent sections as marked by white rectangle 
agniﬁed view of A40/A42 stain as seen in C3. C7: Corresponding magniﬁed view of T
he  comparison of the PiB image nicely matches the ﬂuorescence images indicating the s
:  PET imaging of a prostate cancer mouse model using a PSMA targeting tracer. After a
hole-body coronal preclinical-PET image of an athymic male nude mouse bearing an LN
he  kidney and bladder showing strong signals as well. The graph showing organ activit
limination from most organs and the persistent accumulation in the tumour. After 1 h t
lear  tumour signal. Thus, optimal timing (or even better kinetic analysis) is required to d
rom  (Schäfer et al., 2012)).d Development 160 (2016) 93–116 103
2.5. Preclinical single photon emission computed tomography
(preclinical-SPECT)
2.5.1. Technique
Single Photon Emission Computed Tomography (SPECT) detects
gamma  radiation that is directly emitted by a radionuclide during
decay. SPECT is similar to conventional nuclear medicine planar
imaging by a gamma  camera, but is able to provide 3D information
by acquiring multiple 2D-images while rotating around the imaged
object.
Due to the physical principle of SPECT-imaging, it is neces-
sary to implement collimators in SPECT-scanner systems to gain
spatial information of the gamma  decay. Collimators absorb pho-
tons that are not within a small angular range. For small animal
research pinhole or multiple-pinhole collimators are usually used
(Van Audenhaege et al., 2015), which provide a high spatial reso-
lution (preclinical-SPECT). Resolutions <1 mm can be achieved by
replacing clinical standard collimators (resolution 6–8 mm),  such as
parallel-hole, fan-beam and cone-beam collimators, with a pinhole
collimator (Acton and Kung, 2003).
2.5.2. Applications
SPECT has a wide range of applications due to different avail-
able tracers and, therefore, offers many options to image the ageing
mouse. The main ageing-related applications are myocardial perfu-
sion, neurodegenerative diseases, oncology and bone metabolism.
The risk of a myocardial infarction increases with age. Using
99mTc-Sestamibi Wollenweber et al. (2010) showed the ability
of cardiac perfusion preclinical-SPECT to detect myocardial per-
fusion defects in mice. The infarct volumes measured by SPECT
correlated highly with the results of gold-standard histology. Fur-
thermore, transgenic mice with overexpression of the EP3 receptor
leading to cardiac hypertrophy showed a lower cardiac uptake of
99mTc-Sestamibi compared to wild type mice (Pissarek et al., 2009).
Further tracers for measuring cardiac function are 99mTc-TETRO
(Vrachimis et al., 2012) and 123I MIBG (Dimitriu-Leen et al., 2015).
Neurodegenerative diseases, such as Parkinson’s disease and
Alzheimer’s disease, and other forms of dementia can also be eval-
uated with preclinical SPECT. Several SPECT-tracers are available to
image Parkinson’s disease: 99mTc-TRODAT-1 and 123I FP-CIT bind
to dopamine transporters (DAT), which in healthy people and mice
are strongly expressed in striatum and reduced in this disease
(Hwang et al., 2002). Accurate detection of losses of approximately
60–80% striatal DAT after injection of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) was  found using the tracer 123I FP-CIT
(Andringa et al., 2005). However, the tracer did not permit an
accurate evaluation of the nigral dopaminergic cells in Parkinson’s
disease (Alvarez-Fischer et al., 2007). To differentiate between idio-
pathic Parkinson’s syndrome and atypical Parkinson’s syndromes
(multiple system atrophy, progressive supranuclear palsy), the
dopamine D2 receptor ligand 123I IBZM is used in clinical routine
(Heinzel et al., 2015). 123I IBZM is also an appropriate tracer for D2-
receptor SPECT in healthy mice (Meyer et al., 2008; Pissarek et al.,
2009).
n which allows to distinguish individual plaque sites. The A burden is visualized
with thioﬂavin S ﬂuorescence (FITC excitation, cyan) in C4.
in C1–3. C5: magniﬁcation of digital autoradiograph as seen in C2. C6: corresponding
hioﬂavin S stain as seen in C4.
peciﬁc binding of PiB (Adapted and reprinted from (Manook et al., 2012)).
 dynamic preclinical-PET scan, a static scan was  performed 1 h post-injection. The
CaP tumour xenograft enables clear identiﬁcation of the prostate tumour site with
y as a function of time demonstrates the excretion of the tracer by the kidney, its
he heart, muscle and liver background is reduced, which allows measurement of a
istinguish passive accumulation from active target binding (Adapted and reprinted
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Table 2
Selection of PET tracers used in clinical and preclinical applications.
Nuclide Tracer Fields of use
11C [11C]choline Prostate cancer diagnosis (alternative: [18F]FCH)
[11C]PiB A plaque burden; Alzheimer’s disease
[11C]methionine Amino acid transport; brain tumour diagnosis
[11C]Acetate Oxidative metabolism, fatty acid metabolism
15O 15O2 [15O]Water Oxygen intake and distribution
Perfusion imaging
18F [18F]FDG Glucose utilization; tumours, brain activity, inﬂammation (plaques)
[18F]FCH Prostate cancer diagnosis
[18F]FLT Cell proliferation; cancer diagnosis
[18F]MISO Hypoxia
[18F]DOPA Presynaptic dopaminergic integrity; Parkinson’s disease
[18F]THK523 tau targeting; Alzheimer’s disease
[18F]FHBG -cell imaging, Diabetes
[18F]Galacto-RGD Angiogenesis, inﬂammation; tumours, cardiovascular diseases,
[18F]NaF tumour metastasis and angiogenesis ( 3 expression)
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Dementia affects app. 40 million people, mostly older than 60
ears, worldwide (Scheltens et al., 2016). Alzheimer’s disease is the
ost common form of dementia, followed by vascular dementia
nd dementia with Lewy bodies. In this context, DAT-SPECT with
23I FP-CIT seems to be an ideal method to accurately distinguish
etween these pathologies (Shimizu et al., 2016). 99mTc-HMPAO-
PECT is used in clinical practice to measure cerebral perfusion
Heiss, 2014). However, it is also a promising technique for mea-
uring rCBF (regional cerebral blood ﬂow) in preclinical research
Apostolova et al., 2012) and has been shown to depict age-related
hanges during late maturation (juvenile and young adult) in mice.
n contrast, 99mTc-ECD, another clinical tracer for cerebral perfu-
ion, is more difﬁcult to be applied in mouse-brain SPECT because
f its fast tissue clearance (Apostolova et al., 2012).
In oncology, SPECT is frequently used to image neuroendocrine
umors (NET) by using 111In-octreotide, and [177Lu-DOTA-Tyr3]-
ctreotate for the visualization of somatostatin receptors (Bison
t al., 2015; Ullrich et al., 2016), to image thyroid cancer pre-
nd post-therapeutically using 123I/131I-NaI (Liu et al., 2011; van
er Have et al., 2016) and to perform bone scintigraphy. For the
atter, the tracer 99mTc-MDP is used, which characterizes bone
etabolism in both degenerative changes and cancer (Cowey et al.,
007; Lienemann et al., 2015). Multiple further tracers such as
11In-cCPE-GST, which binds to Claudin 4, that is overexpressed in
everal premalignant precursor lesions are available (Mosley et al.,
015), but it would go over the scope of the article to provide a
omplete overview (Bernsen et al., 2014; Cai and Li, 2013; Franc
t al., 2008).
.5.3. Summary of advantages and limitations
The main advantage of SPECT is that it is less cumbersome
nd less expensive than PET. A wide range of tracers can be
sed for both of these imaging modalities to visualize differ-
nt functional information. SPECT even offers the possibility of
maging multiple radio-labelled probes simultaneously. Energy dis-
rimination can be performed to differentiate between different
adioisotopes emitting gamma  rays at different energies. Many
adionuclides used for SPECT imaging can either be eluted from
enerator-systems or due to their intermediate half-lifes produced
n large amounts and distributed by pharmaceutical companies.
ven though SPECT does not provide morphological information,
t can be combined with CT (SPECT-CT) or MRI  (SPECT-MRI) (Franc
t al., 2008).
On the downside, SPECT has a reduced (10 times lower (Sandhu
t al., 2010)) sensitivity compared to PET in both clinical andmineralization
te cancer diagnosis
preclinical settings (Rowland and Cherry, 2008), because lots of
radiation is lost in absorptive collimation. Furthermore, radiation
exposure cannot be disregarded, which is particularly critical for
long-term observations of mouse models of ageing.
2.6. Ultrasound
2.6.1. Technique
Ultrasound is a mechanical wave operating usually between
2–30 MHz. Because ultrasound is a mechanical wave, there is no
ionizing radiation involved during the imaging of mice. During the
imaging procedure, the animals are lightly anesthetized with 1%
isoﬂurane and in order to provide optimal ultrasound penetration
the hair is removed with a topical depilatory agent. The ultrasound
transducer is usually ﬁxed in a positioning device and acoustic cou-
pling through gel is made to the mouse. High-frequency ultrasound
transducers produce high-resolution images of small structures,
ideal for detecting organ pathology in mice. The role of ultrasound
imaging in the ageing mouse lies mostly in cardiac applications
(Kepez et al., 2008; Ram et al., 2011) (Fig. 4). However, it has
recently been shown (Springer et al., 2014) to have a role in assess-
ing kidney pathology in mouse models.
2.6.2. Cardiac applications
Typical measurements provided by echocardiography in mice
include chamber dimensions, wall thickness, and ejection fraction
(EF). These measurements are useful because one can determine
functional changes in the heart caused by myocardial injury,
genetic modiﬁcations disease, drug treatments, and ageing (Ram
et al., 2011). Recently, myocardial strain measurements (Abraham
et al., 2007; Derumeaux et al., 2008; Friedberg and Mertens, 2013;
Springer et al., 2014) have been utilized to evaluate regional left
ventricular abnormalities that are not normally explored with con-
ventional echocardiographic measurements.
The goal of the study performed by Rosenblatt-Velin et al. (2012)
was to use stem cell antigen-1 (Sca-1) in order to identify cardiac
stem cells in the mouse heart using transthoracic echocardiogra-
phies, by using a 30-MHz transducer. In order to investigate the
function of the antigen in ageing and during the cardiac adaptation
to stress, Sca-1-deﬁcient mice were used. These mice developed
consistently dilated cardiomyopathy. Furthermore, the hearts of
mice lacking Sca-1 demonstrated exacerbated susceptibility to
pressure overload. The heart was imaged in the 2D mode in the
parasternal long-axis view. From this view, M-mode ultrasound
was obtained measuring left ventricle (LV) free wall thickness in
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iastole and in systole as well as LV diameter in diastole and in
ystole.
The natural ageing process results in the physiological decline
f multiple tissues and organ systems including the heart. Changes
ommonly occur with middle age includes among others heart fail-
re. Recent studies by Jackson et al. (2012) suggest that myostatin
ay  inﬂuence cardiac output. In this study an 18 MHz linear epicar-
ial transducer was used, while a 10 MHz-phased array transducer
as used for strain acquisition. Echocardiography was  performed
n anesthetized mice in order to assess basal and maximal cardiac
erformance using isoproterenol stress tests, which cannot be per-
ormed on non-anesthetized mice as handling these mice induces
 stress response. Standard imaging planes, M-mode, Doppler,
nd functional calculations were obtained. The left ventricle (LV)
arasternal long axis four-chamber view was used to derive ejec-
ion fraction (EF) as well as ventricular dimensions and volumes.
he left parasternal short axis view was used to obtain M-mode
entricular wall measures, fractional shortening (FS), and for radial
train analysis. Finally, the subcostal long axis view, from the left
pex, was used for Doppler imaging of mitral inﬂow and aorticxample of US image of abdominal imaging in mice (b).
ejection proﬁles. Stress tests were performed after ﬁrst obtaining
a baseline echocardiogram followed by i.p. injections of isopro-
terenol (10 mg/kg).
The commonly used anaesthetic agent, isoﬂurane, is a potent
coronary vasodilator which could potentially be used in the assess-
ment of coronary reserve, but its effects on coronary blood ﬂow
in mice are unknown. Coronary reserve is reduced by age, coro-
nary artery disease, and other cardiac pathologies. In the study
by Hartley et al. (2007) Doppler ultrasound was used to mea-
sure coronary ﬂow velocity in mice anesthetized at low (1%) and
at high (2.5%) levels of isoﬂurane to generate baseline (B) and
elevated hyperemic (H) coronary ﬂows respectively. A 20 MHz
Doppler probe was  utilized transthoracically toward the origin
of the left main coronary arteries of six weeks, two years, and
two years apolipoprotein-E null (ApoE−/−) atherosclerotic mice.
It was  concluded that Doppler ultrasound combined with coronary
vasodilation via isoﬂurane could provide a convenient and non-
invasive method to estimate coronary reserve in mice, but also that
care must be taken when assessing coronary ﬂow in mice under
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soﬂurane anaesthesia because of its potent coronary vasodilator
roperties.
Tomita et al. (2012) established the relationship between hemo-
ynamics and atherosclerosis in aortic arches of ApoE−/− mice.
ean ﬂow velocities at the ascending and descending aorta (mVAA
nd mVDA) were measured by Doppler ultrasound in wild type and
poE−/− male mice at three and nine months of age.
Another example of the use of ultrasonic imaging of cardiac
unction was proposed by Zhou et al. (2012). In their study, they
eported mitochondrial oxidative stress over a lifetime and con-
luded that it causes aortic stiffening by inducing vascular wall
emodeling, intrinsic changes in smooth muscle cell (SMC) stiffness
nd aortic SMC  apoptosis (Zhou et al., 2012). Pulse wave velocity in
he heart was measured using Doppler with a 30 MHz  probe.
The study by Halade et al. (2011) suggested that rosiglitazone
SG treatment has context dependent effects on cardiac remod-
ling and serves a negative cardiac role when given with a corn
il enriched diet. Mice were lightly anesthetized with isoﬂurane
0.5–2%) and 2D targeted M-mode echocardiographic recordings
ere obtained. Dimensions and wall thickness of the LV were mea-
ured and fractional shortening was calculated.
Dopamine D3 receptor has a critical role in the emergence of
ge related cardiac ﬁbrosis, remodeling, and dysfunction (Johnson
t al., 2013). Animals underwent high-resolution echocardiogra-
hy using a 30 MHz  transducer, in experiment to assess the role of
opamine D3 on cardiac ﬁbrosis.
.6.3. Other applications
Ultrasound imaging plays a role in kidney assessment of age-
ng mice (Springer et al., 2014). Using a 40 MHz linear array
ransducer, high-resolution images were obtained in a diversity
f pathologic lesions occurring within the abdomen of geriatric
ice with acquired hydronephrosis (Springer et al., 2014) that
nabled a determination of the underlying aetiology. Aetiologies
iagnosed from the imaging results include pyelonephritis, neo-
lasia, urolithiasis, mouse urologic syndrome, and spontaneous
ydronephrosis, and were conﬁrmed at necropsy. This report
ighlights the utility of high-frequency ultrasound for surveying
esearch mice for age-related pathology, and is the ﬁrst compre-
ensive report of multiple cases of acquired hydronephrosis in
ice. Moreover, it was recently demonstrated that preclinical high-
requency US can be used to study the development of nonalcoholic
atty liver disease (NAFLD) in mice, with also potential therapeutic
mplications (Fernandez-Dominguez et al., 2011).
.6.4. Summary of advantages and limitations
The main advantages of ultrasound are: a) there is no ionizing
adiation involved, b) it is the fastest imaging modality, c) the cost of
urchasing and operating the device is the lowest, d) it is portable,
nd e) easy to use. Echocardiography is a robust tool for assessing
ardiac (Abraham et al., 2007; Derumeaux et al., 2008; Friedberg
nd Mertens, 2013; Halade et al., 2011; Hartley et al., 2007; Jackson
t al., 2012; Johnson et al., 2013; Rosenblatt-Velin et al., 2012;
omita et al., 2012; Zhou et al., 2012) and kidney (Springer et al.,
014) function in laboratory mice. Conventional echocardiographic
easurements, including chamber dimensions, wall thickness, and
jection fraction are routinely obtained to assess cardiac function
n mice. Recently, myocardial strain and strain rate measurements
Derumeaux et al., 2008) have been added to functional assess-
ents to provide additional details on regional abnormalities that
re not evident using conventional measurements. To date, all stud-
es of strain and strain rate in mice or rats have involved adult
nimals. Myocardial ultrasound imaging in mice is technically fea-
ible and has potential application in studying the pathophysiology
f various cardiovascular and kidney disease.d Development 160 (2016) 93–116
The main limitations of this technique are its user dependency
and the loss of accuracy for scanning some anatomical sites due to
poor penetration through air and bones.
2.7. Intravital microscopy
2.7.1. Technique
Intravital microscopy (IVM) is an optical imaging technique that
enables live animal imaging at high spatial and temporal resolution.
Most commonly it utilizes the visible spectrum plus ultra-violet
and near-infrared wavelengths (∼300–1100 nm). IVM commonly
requires a surgical procedure to access the tissue/organ of inter-
est for microscopy, in which case the animal has to be sacriﬁced
immediately after image acquisition. Most tissues are amenable to
this approach including, for example, intestinal mesentery, lung,
pancreas and skeletal muscles. Implantation of a dorsal skin fold
‘window’ chamber provides the ability to image the same tissue
in vivo repeatedly over days to weeks (Intaglietta and Tompkins,
1973; Padhani et al., 2009; Papenfuss et al., 1979). Here, a metal,
plastic or carbon ﬁbre chamber incorporating a glass ‘window’
holds a skin ﬂap away from the mouse body to enable placement
under a microscope objective for transmitted light microscopy
(Fig. 5).
Dermal layers from one or both sides of the ﬂap are surgi-
cally removed for optical clarity, exposing a striated muscle layer
(panniculus carnosus) in the window. This technique also enables
implantation of tumour or other tissue/cells onto or into the
exposed muscle, resulting in tissue thicknesses of ∼100–300 m.
For instance, adipose tissue-derived microvascular fragments,
seeded onto porous polyurethane scaffolds, were implanted into
dorsal skin fold window chambers in mice to study the effects of
ageing on their vascularization (Laschke et al., 2014). For reﬂected
light microscopy e.g. epi-ﬂuorescence, other types of ‘window’ can
be surgically implanted for exposing the underlying tissue (Alieva
et al., 2014). These include the cranial chamber (Monsky et al.,
2002), mammary gland chamber (Shah et al., 2011), lung obser-
vation chamber (Hatakawa et al., 2002) and ‘body wall’ chamber
(Tsuzuki et al., 2001).
2.7.2. Vascular and cancer microcirculation applications
Most commonly, IVM is used to investigate vascular morphol-
ogy and function, stromal or parenchymal cell interactions with
blood vessels and gene expression using conventional wide-ﬁeld
light microscopy, with either trans- or epi-illumination. Blood ves-
sels provide the greatest endogenous optical contrast amongst the
components of soft tissue enabling measurement of vessel length,
diameter and branching patterns without the need for exogenous
ﬂuorescent contrast agents (Fig. 5). Red blood cell velocity can
also be measured, usually with the aid of ﬂuorescently labeled
red blood cells or plasma. Methods involve the use of algorithms
that either track individual red cells (Reyes-Aldasoro et al., 2008a)
or measure the time difference between matched optical signals
received at different locations along ﬂowing vessels (Fontanella
et al., 2013). Vascular permeability estimations made from mea-
suring the clearance kinetics of an intravenously administered
ﬂuorescent contrast agent such as dextran are also valuable for
monitoring vascular integrity (Reyes-Aldasoro et al., 2008b). Micro-
circulatory abnormalities in cancer, an age-related condition, have
been extensively studied using IVM (Lunt et al., 2010), for a review.
The tumour vasculature is a sought after therapeutic target and
IVM has played a major part in progressing an understanding of
the processes involved in tumour vascularization and oxygenation
(Brizel et al., 1993; Gaustad et al., 2013; Kimura et al., 1996; Sorg
et al., 2005), metastasis (Beerling et al., 2011; Condeelis and Segall,
2003) and response of tumour blood vessels to vascular targeted
therapy (Akerman et al., 2013; Strieth et al., 2006; Vajkoczy et al.,
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Fig. 5. Intravital microscopy. A) an implanted dorsal skin-fold window chamber in a mouse; B) a mouse bearing a dorsal skin-fold window chamber is restrained in a perspex
jig  for microscopy; the chamber is immobilised beneath the microscope objective; C) tumour vasculature visualised by intravenous administration of a ﬂuorescent contrast
agent  and multiphoton ﬂuorescence microscopy; D) low power brightﬁeld view of a tumour growing in a window chamber; the eyelets of the circlip that keeps the glass
coverslip overlying the tumour in place can be seen out-of-focus E): tumour cells were labelled with Dendra2, a photo-switchable ﬂuorophore; non-photoswitched are green
and  photo-switched are red; sequential imaging was used to track the movement of the marked cells. Panel E reprinted by permission from Macmillan Publishers Ltd: Nature
Methods, Kedrin et al., 5 (12): 1019–1021, copyright 2008, (Kedrin et al., 2008). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
t
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999), for example. Other ageing pathologies are strongly associ-
ted with microvascular defects and have been studied using IVM
n mice, for example in cerebral blood ﬂow responses to neuronal
ctivation (Balbi et al., 2015), vasodilatory and microvascular den-
ity responses to insulin, exercise and vascular endothelial growth
actor in skeletal muscle (Wagenmakers et al., 2015) and microcir-
ulatory response to ischaemia in skin (Harder et al., 2010).2.7.3. Advances and other applications
Technical advances in microscopy, cameras, ﬂuorophores, com-
putation and image analysis methodology have meant that
applications for IVM, which has been a research tool in its basic
form for nearly a century, are continually expanding. Microscopes
need to be adapted for live animal research to incorporate facili-
ties for animal restraint or anaesthesia and objective lenses with
sufﬁcient working distances, magniﬁcations and numerical aper-
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ures. Most IVM is performed with cooled CCD (charge-coupled
evice) cameras and associated hardware that can achieve around
0% quantum efﬁciency at video rate. Confocal microscopy, often
ncorporating spinning disc technology or video-rate laser scanning
or fast image capture, or multi-photon ﬂuorescence microscopy
Fig. 5) are now commonly used for IVM (Beerling et al., 2011;
rown et al., 2001; Tozer et al., 2005). As well as enabling 3-D
maging, these techniques circumvent the degradation of image
uality from light scattered by out-of-focus tissue. This problem
an be signiﬁcant for conventional microscopy even in the thin
issue exposed in window chamber preparations. Multiphoton ﬂu-
rescence microscopy has the added advantages of increased tissue
enetration of the long wavelength light used (from ∼40–100 m
or confocal to several hundred m for multiphoton) and reduced
hoto-bleaching and photo-toxicity (i.e. conﬁned to the focal
lane). Multi-photon ﬂuorescence microscopy has been used, for
xample, to study the effect of ageing on the fate of haematopoietic
tem cells in the marrow of long bones (Kohler et al., 2009). Hyper-
pectral imaging incorporates an optical ﬁltering system in front of
he IVM camera, enabling capture of multiple images at different
isible light wavelengths, which is particularly useful for measure-
ent of blood haemoglobin oxygen saturation, for example (Shonat
t al., 1997; Sorg et al., 2005). Optical coherence tomography (OCT)
ses light scatter to generate image contrast and so is distinct from
ther forms of optical microscopy (Fercher et al., 2003). It can be
ikened to ultrasound imaging as it measures the intensity and
iming of back-scattered light instead of sound. Use of long wave-
ength light, typically 800–1300 nm enables relatively good depth
enetration that can exceed 1 mm.  Functional extensions to OCT,
rimarily Doppler and speckle-variance techniques for monitor-
ng microvascular blood ﬂow (Barton and Stromski, 2005), have
xtended the utility of OCT in intravital studies.
Use of ﬂuorescent probes is a mainstay for bio-imaging in intrav-
tal preparations. Conventional organic dyes such as isothyocyanate
FITC) (excitation and emission maxima at 488 and 520 nm respec-
ively) are prone to photo-bleaching but still widely used for image
ontrast either alone or conjugated to proteins of interest. Chem-
cally sensitive derivatives of FITC enable investigations of tissue
H for example and the phosphorescence life-times of various por-
hyrin derivatives are oxygen-sensitive (Helmlinger et al., 1997).
ewer synthetic dyes such as Alexa-ﬂuors and certain ﬂuorescent
ano-crystals (quantum dots) have improved photostability and
mission characteristics. Fluorescent proteins (originally green ﬂu-
rescent protein, GFP, but now expanded to many different types
ith superior properties) have been applied widely for IVM, pri-
arily as reporters of gene expression and for cell tracking but also,
ore recently, for probing molecular interactions via FRET (Förster
esonance Energy Transfer) (Condeelis et al., 2000; Conway et al.,
014; Erami et al., 2015). Amongst these proteins are ones that
xperience reversible or irreversible changes to their emission
pectra on exposure to speciﬁc wavelengths, which may  include
hanges in both intensity (photo-activated, Fig. 5) and emission
avelength (photo-switchable). Use of these recently developed
uorescent proteins are not fully explored for IVM as yet but there
s clear potential for their use in tracking different cell populations
ver time (Kedrin et al., 2008; Pittet and Weissleder, 2011).
.7.4. Summary of advantages and limitations
Intravital microscopy enables highly sensitive in vivo imaging
f tissue structure and function at high spatial resolution (cellu-
ar and sub-cellular) and at relatively low cost. There are many
uitable ﬂuorescent probes available, with increasingly sophisti-
ated properties, and the technique is amenable to use of gene
eporters. Use of near-infrared (NIR) probes reduces the problem
f depth penetration. However, there are some fundamental lim-
tations of IVM, which are not overcome by modern techniques,d Development 160 (2016) 93–116
notably the necessity for surgery. In addition, where window cham-
bers are used, abnormally high tissue pressures may  be induced.
Temperature control, toxicity of contrast agents, photo-toxicity and
immune reactions are also important considerations. Quantifying
IVM data at high spatial resolution and developing analytical meth-
ods for deriving accurate descriptions of biological functions are
on-going challenges, especially with the vast amounts of imaging
data that are now routinely produced and fundamental difﬁculties
associated with quantifying light emission/absorption. Window
chambers have been modiﬁed for use with MRI  scanners (Gaustad
et al., 2008) and simultaneous application of IVM with other imag-
ing modalities such as MRI  and PET provides an opportunity to
exploit the best of each modality.
2.8. Whole body optical imaging
2.8.1. Technique
Whole body optical imaging is based on the excitation of ﬂu-
orochromes by means of an external light source (ﬂuorescence)
or on the light emitted by chemiluminescent enzymatic reactions
within the subject (bioluminescence). In both imaging modes, a
CCD camera is used to acquire the light signal, most commonly
in a 2D planar image. The camera can be cooled down in order to
increase its sensitivity to light and therefore acquire weaker signals
(Willmann et al., 2008). Typical ﬂuorochromes used are green ﬂu-
orescent protein (GFP), red ﬂuorescence protein (RFP), rhodamine,
or engineered ﬂuorochromes for particular applications (see Sec-
tion 2.7). Near-infrared (NIR) ﬂuorescent proteins have allowed
signiﬁcant improvements in tissue penetration for in vivo imag-
ing (Hassan and Klaunberg, 2004) and avoidance of artifacts from
tissue auto-ﬂuorescence (Kovar et al., 2007).
2.8.2. Cancer research
Whole body optical imaging is a sensitive technique but, due to
light scattering, spatial resolution is poor. In mouse models, GFP
has been used to measure the in vivo growth of many different
types of tumours, as well as metastatic spread and the effect of
drug treatments on tumour growth (Hoffman, 2001). Moreover,
genetically engineered light-emitting reporter genes can be used
to study in vivo protein expression in cancer models and the effect
of pharmacological treatments (Willmann et al., 2008). There is a
vast literature about optical ﬂuorescence imaging applications for
studying cancer; we  report here only a few examples. Chen et al.
(2003) used a glucose analogue with NIR ﬂuorescence to local-
ize tumours in mice via their high rate of glycolysis compared
to surrounding normal tissue. In another application Citrin et al.
(2004) labeled endostatin with indocyanine dye (Cy5.5) for detect-
ing tumour vasculature. Pesnel et al. (2012) used a monoclonal
antibody labeled with a NIR ﬂuorochrome for detecting leukemic
foci in a disseminated murine model.
2.8.3. Other applications
GFPs have been used, amongst other ﬂuorescent proteins, for
studying gene expression and protein-protein interactions (van
Roessel and Brand, 2002), viral infection (Haan et al., 2001),
embryonic development (Lipp and Muller, 2004) and in neuro-
science (Cruz-Martin and Portera-Cailliau, 2014). In thrombosis
mouse models, NIR ﬂuorochromes conjugated to a thrombin-
speciﬁc oligopeptide substrate (Jaffer et al., 2002) or conjugated
to a peptide ligand derived from the amino terminus of alpha2-
antiplasmin (Jaffer et al., 2004) have been used in order to image
experimental thrombi. NIR proteins have also been used in muscu-
loskeletal applications. For example, Hansch et al. (2004) showed
that anti-F4/80 monoclonal antibodies labeled with Cy5.5 can be
used to image antigen-induced rheumatoid arthritis in mice. In
addition, a cathepsin-B NIR probe showed potential for diagnosis
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f early osteoarthritis (Lai et al., 2004) and a protease-activated
IR probe was used for early monitoring of treatment response to
ntirheumatic drugs (Wunder et al., 2004). For other applications,
olf et al. (2014) used redox-sensitive GFP for studying oxidative
tress in the skin of mice in vivo. Hall et al. (2012) used a dynamic
ulti-wavelength optical imaging system for visualizing physio-
ogically relevant levels of superoxide in speciﬁc brain regions,
hich can be used to study obesity, diabetes, hypertension and the
geing process itself.
.8.4. Summary of advantages and limitations
Whole body optical imaging is easy to perform, fast and cost
fﬁcient compared to PET or MRI  for example.
The main limitation is low depth penetration (a few mm  in
he case of visible dyes) and light scattering, which severely lim-
ts spatial resolution to the order of 1–10 mm.  It is these issues
hat necessitate the use of intravital microscopy (Section 2.7) for
any optical imaging applications. While NIR ﬂuorochromes have
mproved penetration for in vivo applications (up to several cen-
imetres (Kovar et al., 2007)), dense tissues such as bones still
epresent a problem. While most applications are 2D, 3D systems
re now available, providing much better locational information
Zhang et al., 2013). The cost effectiveness of whole body optical
maging makes it easy to combine with other in vivo imaging modal-
ties such as micro-CT (Barrefelt et al., 2015; Bernthal et al., 2014;
iska et al., 2012) and preclinical-MRI (Bakalova et al., 2015).
. Considerations in using in vivo imaging for studying
geing with mice models
.1. Standardization and three Rs (reduction, reﬁnement and
eplacement) of animals in experimental research
Animal experiments are inherently complex (Denayer et al.,
014). Standardized in vivo imaging may  present an opportunity
o monitor aged mice more effectively. Several sets of stringent
uidelines, such as the “Animal Research: reporting of in vivo exper-
ments (ARRIVE)” guidelines and the “Guidelines for the welfare
nd use of animals in cancer research” are useful for making exper-
mental procedures involving animals more robust (Kilkenny et al.,
010; Workman et al., 2010). Using guidance from ARRIVE, the
nternational mouse phenotyping consortium uses both male and
emale animals in all phenotyping studies to account for sexual
imorphism. With the increasing robustness of in vivo imaging,
t may  become a fundamental add-on to the current procedures
or disease phenotyping in addition to procedures that determine
he endpoints and effects of interventions, such as body weight
Dennis, 2000; Hawkins et al., 2011; Morton, 2000). So far, it is very
ifﬁcult to standardize techniques, measurements and laboratory
nvironments across laboratories. Therefore, despite producing
ood quality data, studies between research groups are often not
omparable due to a lack of a consensus regarding standardization
Hrabe de Angelis et al., 2015; Richter et al., 2009; van der Staay
t al., 2010). Obviously, this results in increased animal usage and
astes resources when studies produce conﬂicting results. With
ged mice representing such a costly investment for laboratories,
t will also become even more important for these studies to be
fﬁcient, well planned and maximized in a way that obtains the
ost possible beneﬁt from each animal. In vivo imaging inherently
aximizes the use of animals due to its non-terminal nature. More-
ver, in vivo imaging techniques can be combined with other in vivo
ssessments, which can maximize the usefulness of the mice taking
art in these studies. For example, traditional in vivo measurements
an be used to assess a range of factors, as reported in life methods
mployed by the IMPC in their International Mouse Phenotypingd Development 160 (2016) 93–116 109
Resource of Standardised Screens and The European Mouse Phe-
notyping Resource of Standardised Screens (Mallon et al., 2008),
such as behaviour, body composition and frailty (Whitehead et al.,
2014).
Maximal use of any available techniques for the reduction,
replacement and reﬁnement of animal experiments should be a
priority for any researcher working with animals (Festing, 2004;
Parker and Browne, 2014). In vivo imaging, having the potential
for reducing measurement variability by tracking the same animal
longitudinally when compared to standard cross-sectional design,
can reduce animal numbers. In vivo imaging measurements are also
capable of reﬁning animal experiments as in some cases they can
reduce pain, suffering, distress and lasting harm that may  be expe-
rienced by the animals using other methods. Additionally, better
end point evaluation and health measures will increase the qual-
ity of animal experiments, increase animal welfare and hopefully
reduce the requirement to repeat experiments.
3.2. Animal considerations in longitudinal in vivo imaging with
age
Although the imaging modalities presented in this review
offer great potential for longitudinal studies, there are still
some challenges in their application to mouse models such as
complexity of animal monitoring (preclinical-MRI), radiation expo-
sure from the scan (micro-CT) or from the radioactive markers
(preclinical-PET and -SPECT), and invasiveness of the procedure
(intravital microscopy). Animal considerations when using longitu-
dinal in vivo imaging in preclinical research have been extensively
reviewed for young and adult animals (Hildebrandt et al., 2008;
Tremoleda et al., 2012). However, little is known about the extent
ageing may  have as a confounding factor. With age, we  observe
a decline in major physiological functions, including cognitive
(Shoji et al., 2016), cardiovascular (Dai and Rabinovitch, 2009),
and respiratory (Lowery et al., 2013), an impaired ability to
repair stress-induced damage at the cellular level (Kourtis and
Tavernarakis, 2011), an altered metabolic footprint (Houtkooper
et al., 2011) and thermoregulation (Van Someren, 2007), and an
increased level of sensitivity to stress inducers (Shoji et al., 2016).
Therefore, special considerations may  apply when using these
modalities on aged animals, some of which are reported below.
3.2.1. Animal handling
Regardless of the imaging modality, the stress associated with
handling of the animals in laboratory routines, preparation for
imaging (e.g. restraint, injections, surgeries) and the imaging itself
creates physiological and metabolic modiﬁcations (Meijer et al.,
2005, 2006). These changes can affect experimental outcomes,
especially in longitudinal settings (i.e. repeated handling) where
different measurements are performed on each mouse at each time
point (i.e. scans with different techniques). The capacity adult mice
have to cope with stress induced damage, associated with care-
ful monitoring ensures minimal effect of handling. However, in
aged mice, because they present an impaired ability to cope with
stress, appropriate controls and validations must be carried out to
ensure these changes have minimal effects on the outcome of the
experiment.
3.2.2. Anaesthesia
Although required to facilitate immobilisation and image acqui-
sition, anaesthesia is accompanied by a depression in respiration
rate, heart rate and cardiac output, and a decrease in core temper-
ature (Caro et al., 2013). These changes result in decreased speed
of oxygen delivery to tissues, increasing risk of hypoxia. This risk
is aggravated with age, as oxygen delivery to the tissues declines
(North and Sinclair, 2012), along with respiratory and cardiac func-
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ions, thus affecting recovery. Therefore, extra care must be given
o aged animals, in terms of monitoring pre- and post-imaging,
specially in longitudinal settings. For instance, using inhalation
naesthesia (such as Isoﬂurane) mixed with medical grade oxy-
en will help to reduce the risk of hypoxia related to anaesthesia.
t will also allow individual responses to anaesthesia to be efﬁ-
iently monitored. The animal’s temperature should also be kept
onstant during imaging (e.g. with hot air or heating pads). Finally,
hile adult mice can withstand several hours of anaesthesia with-
ut apparent short-term effects (Lu et al., 2015b), anaesthesia time
hould be decided and tested on aged animals to minimise inter-
erences with the experimental outcomes.
.2.3. Radiation dose
Whether the exposure is intrinsic, when radiotracers are
njected for Micro-PET imaging, or is extrinsic, as it is in micro-
T imaging, radiation exposure is a potential limitation of these
ethodologies. Irradiation is known to cause DNA damage, which
s repaired in a couple of days in adult mice (Grudzenski et al., 2010).
hen longitudinal studies are planned, a compromise between
mage quality and radiation dose is often reached. This compromise
ay  be more delicate to establish when studying aged mice, as the
issues ability to repair DNA damage declines with age (Grudzenski
t al., 2010). The scanning time as well as the time interval between
wo imaging sessions should therefore be carefully decided to min-
mise the radiation related effects.
.2.4. Animal frailty
The ageing process is accompanied by a frailty state that makes
he animal more sensitive to external stimuli such as exposure
o handling stress or to radiation. Frailty might be exacerbated in
ongitudinal settings and it is therefore essential to monitor the
ellbeing of the animal throughout the experiment and report
ny changes. This monitoring can be non-invasive and fast, using
 recently published approach that quantiﬁes the frailty index for
ach animal (Whitehead et al., 2014).
.2.5. Age of the mouse models
The reviewed literature about applications of in vivo imaging
odalities for studying ageing and age-related disorders (Table 2)
evealed that most of the mice models were used in their adult-
ood (less than 12 months old), during which all physiological
rocesses are healthy and all markers of ageing (e.g. DNA damage,
xidative stress, inﬂammatory cytokines and cellular senescence)
Lopez-Otin et al., 2013) are absent or minimal. This means that
lthough the current models provide precious information on the
iseases onset and progression, they might underestimate ageing
s a confounding factor. It is therefore recommended to use aged
ice, yet to carefully choose the age window for each project, and
ake extra care when using very old mice, as they present a high
railty index, and numerous tissue dysfunctions that may  be unre-
ated to the study and interfere with the outcome of the experiment
y increasing the variability in the data (Miller and Nadon, 2000).
. Conclusions
Aged mouse models are a powerful tool that can be used to bet-
er understand the ageing process. However, the novelty of these
ouse models will also pose new challenges to researchers in var-
ous forms including phenotyping and endpoint evaluation. State
f the art in vivo imaging on aged mice enables well-controlled and
ccurate longitudinal measurements of tissue and organ pheno-
ypes associated with healthy ageing and age-related diseases. It
s also possible to combine different imaging techniques, in order
o study dysfunction of multiple tissues or the effect of certain
athologies or treatments on different systems. Combining in vivod Development 160 (2016) 93–116
imaging with other in vivo methodologies will also help to max-
imise the data gained from individual mice.
4.1. Future work and perspectives
It has become clear that the single imaging modalities pre-
sented in this review have the potential to be combined with each
other and with other standard laboratory techniques, in order to
exploit the best features of each modality. The standardization
of spatial and temporal measurement from such complex tech-
niques is necessary in order to provide reliable and sharable data.
Central facilities that contain all the different imaging techniques
and expert researchers with multidisciplinary skills (e.g. biology,
physics, engineering) to run them and interpret the data obtained
are highly desirable. Besides providing novel research ﬁndings,
these in vivo techniques will also help with the reduction of animal
usage and reﬁnement of techniques.
A number of challenges remain to be addressed, regarding both
the individual techniques and combinations thereof. A lot of work
needs to be done on animal handling protocols during scanning
in vivo, e.g. to reduce anaesthesia artifacts, and on the design of
optimal instrumented animal holders and chambers that can be
used in all systems. In particular, speciﬁc standardized procedures
should be deﬁned for handling aged mice, showing signs of frailty
and dysfunction of multiple tissues. Another point that should be
considered is the evaluation of the true non-invasiveness of the
imaging modalities. This requires more methodological work, in
order to investigate how much each modality affects the measure-
ments being made; for example, the use of contrast agents at high
concentrations in MRI, or the use of foreign proteins for molecular
imaging studies. A further challenge is related to image analyses
and merging of data obtained from multi-modality imaging into
a single dataset. Due to unavoidable deformation of soft tissues,
standard rigid and afﬁne registrations are probably not sufﬁcient
and application of nonlinear registration algorithms becomes fun-
damental.
Overall, multi-modality in vivo imaging in mouse models has
the potential of providing biomarkers fundamental to investigate
the ageing mechanisms and the effects of dysfunction of multiple
tissues and organs and systems.
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